Dr. Cameron is an economist with 25 years of experience consulting to attorneys and companies involved in commercial litigation, regulatory proceedings, and other complex matters.

Her broad industry expertise includes pharmaceuticals, biologics, medical devices, motor vehicles, consumer products, software, e-commerce, cryptocurrencies, telecom, and energy. Dr. Cameron has worked on a wide array of intellectual property, false advertising, competition, and transfer pricing matters. She has analyzed damages, liability, and requests for injunctive relief. In patent disputes, Dr. Cameron has testified on both commercial success and damages. She has also testified in matters involving competition and investment incentives before the Federal Energy Regulatory Commission and state public utility commissions.

Prior to becoming a consultant, Dr. Cameron was a professor of economics at Carnegie Mellon University’s Tepper School of Business, where she taught courses in microeconomic theory, regulation, and antitrust policy.


Stanford University 
PhD in Economics

Cornell University
BSc in Business/Economics


January 2024
In Re Lumify |Civil Action No. 21-16766 (RK) (RLS) (CONSOLIDATED|-cv-1164 | Declaration on Irreparable Harm and Bond (Jan, 2024); Deposition (Jan, 2024); Bench Trial (Jan 2024).
March 2023
Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals, USA, Inc. v. Eli Lilly and Company | Declaration on Damages (January 2023); Reply Declaration on Damages (March 2023)
May 2022
Regeneron Pharmaceuticals, Inc. v. Novartis Pharma AG, Novartis Technology LLC, Novartis Pharmaceuticals Corporation (Regeneron v. Novartis) | IPR2021-00816 | Declaration on Commercial Success (April 2022); Deposition (May 2022)
February 2018

The University of Sydney et al v. ObjectiVision Pty Ltd. (No. NSD 385 of 2014). Report on Damages.